Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of tinzaparin on biomarkers in advanced ovarian cancer receiving neoadjuvant chemotherapy
2021-000135-31Phase 2Active
- Sponsor
- Region Östergötland
- Start
- May 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of tinzaparin in epithelial ovarian cancer (EOC) (2 arms), sponsored by Region Östergötland. Primary endpoint: Change in CA-125 level. Started May 2021; status: active.
02
Drugs
tinzaparin
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on 2021-000135-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000135-31.